| November 30, 2010 |
Savient Announces Price and First Shipment of KRYSTEXXA |
| September 14, 2010 |
FDA Approves KRYSTEXXA for Chronic Refractory Gout |
| March 30, 2010 |
Savient Announces PDUFA Date of 09-14-10 |
| March 15, 2010 |
Savient Resubmits Biologics License Application for KRYSTEXXA |
| January 8, 2010 |
Savient Update on KRYSTEXXA BLA Filing |
| September 16. 2009 |
Savient provides update on FDA meeting |
| September 8, 2009 |
Savient press release re ACR Abstracts |
| August 2, 2009 |
Savient Receives Complete Response from FDA |
| June 16, 2009 |
FDA Arthritis Advisory Committee Recommends Approval of Pegloticase |
| May 29, 2009 |
Savient to Present Multiple Abstracts at 2009 EULAR Congress |
| January 28, 2009 |
Savient Announces FDA Advisory Panel |
| December 29, 2008 |
FDA Grants Priority Review to Pegloticase BLA Filing |
| October 31, 2008 |
Savient Submits Biologics License Application |
| October 27, 2008 |
Savient press release on ACR 10-27-08 |
| September 22, 2008 |
Savient to Present Abstracts Related to Puricase® at ACR Meeting in October 2008 |
| May 7, 2008 |
Savient Reports Favorable Interim Data from Puricase® Open Label Extension Study |
| April 21, 2008 |
Savient Provides Update on Puricase® BLA |
| February 4, 2008 |
Savient Reports Additional Positive Phase 3 Results for Puricase® |
| December 13, 2007 |
Savient Press Release - Successful Phase 3 Trials of Puricase® |
| October 16, 2007 |
Savient Completes Puricase® Phase 3 Study |
| March 6, 2007 |
Savient Completes Enrollment for Puricase® Phase 3 Study |
| August 4, 2006 |
Savient Completes Rosemont Sale |
| June 14, 2006 |
Savient Initiates Patient Dosing for Puricase® Phase 3 Study |
| May 3, 2006 |
Savient Receives FDA Final Approval for Puricase® |
| March 21, 2006 |
Savient and FDA Agree on Phase 3 Protocol SPA Puricase® (PEG-uricase) on Track to Enter Phase 3 |
| November 14, 2005 |
Savient's Puricase® (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment Resistant Gout |
| July 28, 2005 |
Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase® |
| May 12, 2005 |
Savient Reports Positive Top-Line Results for Puricase® Phase 2 Trial |
| January 10, 2005 |
Savient Pharmaceuticals, Inc. Completes Patient Dosing in Phase II Clinical Trial of Puricase for Severe Gout |
| July 7, 2003 |
Savient Pharmaceuticals, Inc. Successfully Completes Phase I Clinical Study of Puricase® for Severe Gout |
| August 17, 1998 |
Bio-Technology General Acquires Rights to Technology for Important New Drug, PEG-Uricase, from Duke University and Mountain View Pharmaceuticals, Inc. |